Vimarsana
Biggest News Aggregation in the World

Page 3 - Breakthrough Therapy News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Breakthrough Therapy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Breakthrough Therapy Today - Breaking & Trending Today

Hallucinogens in Mental Health Treatment: Drug Pipeline Updates - Vimarsana News

Hallucinogens in Mental Health Treatment: Drug Pipeline Updates

Hallucinogens in mental health are increasingly being investigated in the drug pipeline, especially for depressive disorders and PTSD.

BioXcel Therapeutics to Present at Jefferies Global Healthcare Conference - Vimarsana News

BioXcel Therapeutics to Present at Jefferies Global Healthcare Conference

28.05.2024 - NEW HAVEN, Conn., May 28, 2024 (GLOBE NEWSWIRE) - BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced ... Seite 1

Axsome Therapeutics Presents Data from Multiple Programs at the 2024 American Society of ... - Vimarsana News

Axsome Therapeutics Presents Data from Multiple Programs at the 2024 American Society of ...

NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders,

First Choice Chiropractic: Leading Excellence in Holistic - Vimarsana News

First Choice Chiropractic: Leading Excellence in Holistic

Press release - Getnews - First Choice Chiropractic: Leading Excellence in Holistic Wellness - published on openPR.com

Source: openpr.com
Brensocatib Reduces the Rate of Pulmonary Exacerbations in Bronchiectasis - Vimarsana News

Brensocatib Reduces the Rate of Pulmonary Exacerbations in Bronchiectasis

Brensocatib is an oral, reversible inhibitor of dipeptidyl peptidase 1.

Source: empr.com